Hakeem Health’s $1.65M round puts bilingual clinical AI on UAE hospital watchlists

Hakeem Health raised $1.65 million on 10 May 2026, putting its bilingual clinical decision-support platform on the watchlist for UAE hospital technology buyers.

The round matters most for CIOs, medical directors, and hospital CEOs reviewing AI tools that must work inside regulated clinical workflows. For UAE buyers, the question is practical: can HakeemDx connect to hospital systems without creating a separate data silo or adding risk to physician decision-making?

What the round funds

According to Wamda, the $1.65 million round was led by Saudi-based Merak Capital, with participation from Sanabil 500. Hakeem Health was founded in 2022 by Bilal Adi and Mohammed Ayyad. Wamda said the company sells SaaS software to hospitals, universities, and healthcare payers.

HakeemDx, the company’s main product, provides Arabic and English clinical guidance at the point of care. Wamda said the platform integrates with hospital systems, including EMRs and laboratory platforms. That integration claim will matter in the UAE because a decision-support tool has limited enterprise value if clinicians must leave the patient record to use it.

• Round size disclosed by Wamda: $1.65 million.
• Named investors: Merak Capital and Sanabil 500.
• Target markets named by Wamda: Saudi Arabia, the UAE, and Egypt.
• Product languages: Arabic and English clinical guidance.

“This funding enables us to expand our platform HakeemDx across hospitals and health systems in the GCC and continue building AI solutions that clinicians trust.” Bilal Adi, founder and CEO of Hakeem Health

Why UAE operators should watch it

The UAE test is regulatory fit. Dubai Health Authority (DHA) runs NABIDH in Dubai. Department of Health Abu Dhabi (DOH) describes Malaffi as Abu Dhabi’s health information exchange. Ministry of Health and Prevention (MOHAP) says Riayati is tied to the National Unified Medical Record. Any clinical AI vendor selling into the UAE has to show how its product works with these exchange layers.

For CIOs, the first test is whether HakeemDx can receive patient context from existing systems while preserving audit trails and access controls. For medical directors, the issue is whether recommendations are traceable to accepted clinical sources. For CEOs, the buying case depends on whether the tool can reduce care variation across departments without slowing physicians.

Wamda said Hakeem Health is targeting more than 2,000 hospitals across Saudi Arabia, the UAE, Egypt, and other regional markets. That addressable base is large, but UAE adoption will depend on local proof. Hospitals under DHA, DOH, and MOHAP oversight will ask for implementation references, privacy documentation, role-based access, audit logs, and evidence that HakeemDx does not disrupt mandated health information exchange workflows.

What buyers should track next

The next 12 months should show whether Hakeem Health can move from funded startup to approved enterprise vendor. UAE procurement committees rarely buy clinical systems on product claims alone. They will want clinician acceptance data, cybersecurity documentation, local deployment references, and a clear answer on liability when AI-supported advice conflicts with physician judgment.

For health tech founders, the round points to demand for workflow software that integrates with EMRs, supports Arabic, and fits regulator-led data exchange. For hospital buyers, the immediate takeaway is narrower: add bilingual clinical decision support to the 2026 digital health watchlist, then evaluate HakeemDx against DHA, DOH, and MOHAP integration requirements before discussing price.